The role of ALP as predictor of CV events and vascular calcification in CKD

10' education - June 15, 2019 - Dr. Mathias Haarhaus, MD – Stockholm, Sweden

Alkaline phosphatase (ALP) is a potential novel treatment target for CVD in CKD. Dr. Haarhaus discusses ALP-related mechanisms of increased CV risk and beneficial effects of the BET inhibitor apabetalone.

Video navigation menu

What is alkaline phosphatase and where can it be found? 1:08
ALP-related mechanisms of increased CV 2:38
Reduced ALP-related CV risk with apabetalone 8:44

Educational information

This lecture by dr. Mathias Haarhaus, was part of an accredited symposium "Vascular calcification in kidney disease: Epigenetics as a novel approach?" held during ERA-EDTA 2019 in Budapest, Hungary.

Faculty

Dr. Mathias Haarhaus, MD, Consultant Nephrologist at the Department of Nephrology, Karolinska University Hospital, Stockholm, Sweden

Disclosures

This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.

Funding

Funding for this educational program was provided by an unrestricted educational grant from Resverlogix.

View slides of the presentation

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.